Strep Throat Treatment Market Report 2026

The strep throat treatment market size has grown strongly in recent years. It will grow from $2.19 billion in 2025 to $2.31 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing prevalence of bacterial throat infections, widespread availability of penicillin-based antibiotics, expansion of primary healthcare access, growing pediatric patient population, established clinical treatment guidelines.

The strep throat treatment market size is expected to see strong growth in the next few years. It will grow to $2.81 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to rising focus on antimicrobial resistance management, increasing use of rapid point-of-care diagnostics, expansion of telehealth consultations, growing demand for accurate early diagnosis, increasing investments in infectious disease research. Major trends in the forecast period include increasing adoption of rapid diagnostic testing, rising focus on antibiotic stewardship programs, growing use of combination therapy approaches, expansion of telemedicine-based diagnosis, enhanced patient awareness and early treatment.

The increasing incidence of bacterial infections is expected to drive growth in the strep throat treatment market in the coming years. Bacterial infections are illnesses caused by harmful bacteria that invade the body, multiply, and release toxins. The rise in these infections is associated with factors such as antibiotic overuse, global travel, urbanization, poor hygiene, and healthcare-associated infections. Strep throat treatment helps manage bacterial infections by delivering effective medications and care that relieve symptoms, shorten illness duration, prevent complications, and support healthcare providers in controlling infection spread. For example, in June 2023, the Office for Health Improvement and Disparities, a UK-based government body, reported 4,622 notifications of scarlet fever caused by Group A Streptococcus between weeks 37 and 46 of the 2022-2023 season in England, with 851 notifications in week 46 alone. This figure was significantly higher than the five-year average of 1,294 notifications for the same period. Therefore, the rising incidence of bacterial infections is fueling growth in the strep throat treatment market.

The growth of the strep throat treatment market is also expected to be supported by rising healthcare expenditure. Healthcare expenditure represents the total spending by individuals, organizations, and governments on the prevention, treatment, and management of health conditions. Increased spending is driven by advances in medical technology, as newer diagnostic tools, treatments, and innovative therapies often come with higher costs, contributing to greater overall healthcare outlays. Higher healthcare expenditure enhances strep throat treatment by supporting timely diagnostics, access to affordable antibiotics, trained healthcare professionals, public health initiatives, and research efforts aimed at preventing complications and expanding access to care. For instance, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid, reported that U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per person. As a result, increasing healthcare expenditure is driving growth in the strep throat treatment market.

Leading companies in the strep throat treatment market are focusing on developing innovative solutions, such as rapid throat infection diagnostic tools, to deliver fast, accurate, and multiplex testing for respiratory and sore throat infections at the point of care. These rapid diagnostics, including rapid strep tests, quickly identify the presence of Group A Streptococcus bacteria in the throat, enabling prompt diagnosis and appropriate treatment while helping to reduce unnecessary antibiotic use. For example, in June 2024, bioMérieux, a France-based in vitro diagnostics company, announced the launch of the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini. This rapid diagnostic test detects five common viral and bacterial causes of respiratory and sore throat infections and is designed to deliver quick, actionable results directly at the point of care.

Major companies operating in the strep throat treatment market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc GSK, C.H. Boehringer Sohn AG And Co. KG, Eli Lilly and Company, Amgen Inc., Reckitt Benckiser Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Mylan N.V.

North America was the largest region in the strep throat treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the strep throat treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the strep throat treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the strep throat treatment market by increasing costs of imported active pharmaceutical ingredients, diagnostic reagents, laboratory consumables, and packaging materials used in antibiotic and testing kit production. Pharmaceutical manufacturers and diagnostic laboratories in North America and Europe are most affected due to reliance on global ingredient sourcing, while Asia-Pacific faces cost pressure in export-oriented drug manufacturing. These tariffs are contributing to higher production costs and pricing pressure for branded and generic antibiotics. However, they are also encouraging local API manufacturing, regional diagnostic kit production, and supply chain diversification to strengthen treatment availability.

The strep throat treatment market research report is one of a series of new reports that provides strep throat treatment market statistics, including strep throat treatment industry global market size, regional shares, competitors with a strep throat treatment market share, detailed strep throat treatment market segments, market trends and opportunities, and any further data you may need to thrive in the strep throat treatment industry. This strep throat treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Strep throat is a bacterial infection caused by Group A Streptococcus bacteria that commonly affects the throat and tonsils. It usually presents with symptoms such as sore throat, difficulty swallowing, fever, swollen lymph nodes, and occasionally white patches on the tonsils. Treatment typically involves antibiotics such as penicillin or amoxicillin, along with pain relievers, adequate rest, and fluids to relieve symptoms, prevent complications, and support recovery.

The main types of strep throat treatments include antibiotics, pain relievers, and others. Antibiotics are medications that destroy or inhibit bacterial growth and serve as the primary therapy for strep throat by targeting the causative streptococcal bacteria. Diagnostic methods include antibody tests, physical examinations, throat cultures, and others. Routes of administration include oral, topical, and injectable forms, and treatments are used for conditions such as acute strep throat, pharyngitis, tonsillitis, laryngitis, and related disorders. End users include hospitals, specialty clinics, diagnostic laboratories, and others.

The strep throat treatment market consists of revenues earned by entities through services such as, antibiotic prescriptions, pain relief management, supportive care, and follow-up consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The strep throat treatment market also includes sales of throat lozenges and supportive care items such as throat sprays and herbal remedies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.